SystImmune

What SystImmune does

SystImmune is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Redmond, Washington, that develops antibody-based oncology therapeutics. The company is a subsidiary of Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), a Chinese biotech, with US operations in Redmond and Princeton, New Jersey, and China operations in Shanghai and Chengdu. SystImmune's lead asset is iza-bren (izalontamab brengitecan / BL-B01D1), the world's first EGFR×HER3 bispecific antibody-drug conjugate (ADC), which received its first regulatory approval from China's NMPA in June 2026 for recurrent/metastatic nasopharyngeal carcinoma — the first bispecific ADC approval globally.

The technology base rests on four proprietary platforms: SEBA (bispecific antibody platform with selective binding domains separating activity from toxicity), HIRE ADC (proprietary topoisomerase I inhibitor payload Ed-04 with AC attachment, dipeptide hydrophilic spacer, and GGFG quick-release tetrapeptide linker), GNC (multi-specific antibody discovery), and AIDP (AI-powered drug discovery and design). The pipeline extends beyond iza-bren to T-Bren / BL-M07D1 (HER2 ADC), BL-M11D1 (CD33 ADC for AML), BL-M14D1 (DLL3 ADC for SCLC), BL-M05D1 (Claudin18.2 ADC), and earlier-stage candidates. Three Phase III trials have met primary endpoints to date — nasopharyngeal carcinoma, triple-negative breast cancer, and esophageal squamous cell carcinoma — and the lead asset holds FDA Breakthrough Therapy Designation plus seven CDE Breakthrough designations in China.

Commercially, SystImmune operates under a bifurcated geographic model. Biokin holds exclusive development, commercialization, and manufacturing rights in Mainland China and sponsors Chinese Phase III trials, while Bristol Myers Squibb holds exclusive development and commercialization rights outside China under a December 2023 collaboration valued at up to $8.4 billion ($800M upfront, up to $500M near-term payments, and up to $7.1B in development/regulatory/sales milestones). Revenue mechanics include upfront and milestone payments plus tiered royalties on net sales in BMS territories; SystImmune receives royalties on BMS sales into China. Product sales in China have just begun following the June 2026 NMPA approval.

Name

SystImmune

Legal name

SystImmune Inc.

Website

https://systimmune.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

SystImmune is a clinical-stage biopharmaceutical subsidiary of Sichuan Biokin Pharmaceutical that develops bispecific antibody-drug conjugates and multi-specific antibodies for solid tumors. Its lead asset iza-bren is the first bispecific ADC approved globally (China, June 2026), commercialized in China by Biokin and ex-China by Bristol Myers Squibb.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals / Antibody-Drug Conjugates

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

Keywords

• Antibody-drug conjugates
• Bispecific antibodies
• Oncology therapeutics
• Cancer drug development
• Biopharmaceutical research

Headquarters

HQ city

Redmond

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Partnership Milestone Payments: BMS paid $800 million upfront and up to $500 million in contingent near-term payments. SystImmune is eligible for additional payments of up to $7.1 billion contingent upon achievement of development, regulatory and sales performance milestones. $250 million milestone received in October 2025 for first patient treated.
2. Royalties on Net Sales: BMS pays royalties on net sales in Mainland China. Outside the US and Mainland China, SystImmune receives tiered royalties on net sales.
3. Product Sales (China): Following NMPA approval in China for nasopharyngeal carcinoma, SystImmune's parent company Biokin will commercialize iza-bren in Mainland China, generating product revenue.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

SystImmune is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and multi-specific antibodies for the treatment of solid tumors and hematologic malignancies. Its lead asset iza-bren (BL-B01D1) is the world's first EGFR×HER3 bispecific ADC to receive regulatory approval (China NMPA, June 2026), supported by four proprietary platforms (SEBA, HIRE ADC, GNC, AIDP) and a multi-asset pipeline across oncology indications.

Product overview

SystImmune is a clinical-stage biopharmaceutical company developing a portfolio of innovative antibody-drug conjugates (ADCs) and multi-specific antibodies for cancer treatment. The core product portfolio includes Iza-bren (BL-B01D1), the world's first EGFR×HER3 bispecific ADC which received its first regulatory approval in China in June 2026; T-Bren (BL-M07D1), a HER2-targeted ADC; and additional ADC candidates targeting CD33 (BL-M11D1), DLL3 (BL-M14D1), Claudin18.2 (BL-M05D1), and other undisclosed targets. The technology foundation consists of three proprietary platforms: the HIRE ADC platform with topoisomerase I inhibitor payloads and novel linker technology, the SEBA bi-specific antibody platform, and the GNC multi-specific antibody platform, all supported by the AIDP AI-powered drug discovery system. Iza-bren is co-developed with Bristol Myers Squibb outside China under a collaboration agreement valued at up to $8.4 billion.

Differentiator

Problem solved

Functional benefit

Products and services

• Iza-bren (Izalontamab Brengitecan, BL-B01D1) World's first EGFR×HER3 bispecific antibody-drug conjugate with topoisomerase I inhibitor payload; targets EGFR and HER3 receptors highly expressed in epithelial tumors. Approved in China for recurrent/metastatic nasopharyngeal carcinoma (June 2026) and in Phase III development for triple-negative breast cancer, esophageal squamous cell carcinoma, NSCLC, and other solid tumors. Jointly developed with Bristol Myers Squibb outside Mainland China.
• T-Bren (BL-M07D1, Trastuzumab Brengitecan) HER2-targeted antibody-drug conjugate built on the proprietary brengitecan payload platform. Positioned as a potential backbone therapy across HER2-expressing tumor types including breast cancer and gastric cancer. Fully owned by SystImmune.
• BL-M11D1 CD33-targeted antibody-drug conjugate for relapsed/refractory Acute Myeloid Leukemia (AML). Comprises CD33-binding antibody with topoisomerase I inhibitor payload and enzyme-cleavable linker. In Phase Ia/Ib clinical trials in the United States and China.
• BL-M14D1 DLL3-directed antibody-drug conjugate for small-cell lung cancer and neuroendocrine tumors. Developed on the proprietary brengitecan platform with the same linker-toxin architecture as iza-bren.
• BL-M05D1 Claudin 18.2-directed antibody-drug conjugate for Claudin18.2-expressing solid tumors including pancreatic and gastric cancers. Features an in-house developed Claudin 18.2-targeted monoclonal antibody paired with the brengitecan payload and proprietary linker chemistry.
• BL-M08D1 Antibody-drug conjugate targeting lymphoid malignancies and locally advanced or metastatic solid tumors. Developed on the brengitecan platform shared with iza-bren. Currently in IND stage.
• BL-M09D1 In-house engineered antibody-drug conjugate for colorectal cancer and other advanced solid tumors. Currently in preclinical/IND-enabling stage.
• BL-M17D1 Antibody-drug conjugate with next-generation linker and payload technology for HER2-expressing or HER2-mutant advanced/metastatic solid tumors. Phase 1 clinical trial BL-M17D1-ST-101 ongoing in the United States.

Quantifiable outcome

• Median OS improvement from 12.5 to 15.9 months (HR 0.60) in triple-negative breast cancer
• +6 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Four partnerships are on record, tiered flagship and minor.

• Bristol Myers SquibbflagshipStrategic or Co-development Partner · 11 December 2023Exclusive license and collaboration agreement for BL-B01D1 (iza-bren), a potentially first-in-class EGFRxHER3 bispecific ADC. Companies jointly develop and commercialize in the US, SystImmune retains exclusive rights in Mainland China, BMS gains exclusive license in rest of world. Financial terms include $800M upfront, up to $500M near-term payments, and up to $7.1B in milestones (total $8.4B potential). Companies share US development expenses and profits/losses.
• Sichuan Biokin Pharmaceutical Co., Ltd.flagshipOthersParent company relationship. Biokin is the parent/affiliate of SystImmune and conducts clinical development and manufacturing in China. Biokin received NMPA approval for iza-bren in nasopharyngeal carcinoma (June 2026) and sponsors Phase III trials in China.
• Henlius (Shanghai Henlius Biotech)minorStrategic or Co-development PartnerClinical collaboration for combination therapy study evaluating iza-bren with serplulimab (anti-PD-1 antibody) in extensive-stage small cell lung cancer patients
• AstraZenecaminorStrategic or Co-development PartnerMentioned as comparable deal in market analysis context - AstraZeneca committed US$1.5 billion to build first end-to-end ADC manufacturing facility in Singapore; LaNova Medicines partnership with AstraZeneca valued at US$600 million

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Daiichi Sankyo: Daiichi Sankyo is the global leader in ADC development with its DXd platform (Enhertu, Dato-DXd) and is the most directly comparable peer to SystImmune; both companies build proprietary ADC linker-payload technologies and pursue first-in-class bispecific/targeted oncology ADCs in solid tumors, competing for the same oncologists, indications, and combination-therapy opportunities.

Broad incumbents

• Pfizer (Seagen): Pfizer acquired Seagen in 2023 for $43B to build an ADC franchise (Adcetris, Padcev, Tukysa) and is now a major competitor in oncology ADCs; while much larger, Pfizer/Seagen competes with SystImmune for similar oncology indications and physician adoption, and represents the kind of large-pharma acquirer or partner that could transact on SystImmune assets.
• AstraZeneca: AstraZeneca is a strategic ADC player via its long-standing Daiichi Sankyo collaboration (Enhertu, datopotamab) and has been actively transacting with Chinese biotechs (e.g., LaNova at $600M, Gracell $1.2B); the company is a relevant peer as both a competitor in the ADC space and a potential strategic acquirer of SystImmune or its pipeline assets.
• Gilead Sciences: Gilead acquired Immunomedics in 2020 for $21B to access Trodelvy, a TROP2-directed ADC for TNBC and other solid tumors, and is now a direct competitor to iza-bren in the TNBC space where SystImmune has demonstrated strong Phase III results; both companies target similar HER2-low/TROP2/EGFR-expressing patient populations.
• AbbVie (ImmunoGen): AbbVie acquired ImmunoGen in 2023 for $10.1B to gain Elahere (mirvetuximab soravtansine), a folate receptor alpha-directed ADC for ovarian cancer; the deal established a valuation benchmark for clinical-to-commercial ADC assets and represents the exit path/large-pharma comparator relevant to SystImmune's strategic options.

Emerging players

• Mersana Therapeutics: Mersana is a clinical-stage ADC company developing next-generation ADCs with novel payloads (Dolasynthen, Immunosynthen platforms) for oncology; it represents an emerging peer in the same ADC-innovation category as SystImmune's HIRE platform, focused on differentiated linker-payload chemistry and first-in-class target opportunities.
• Akeso, Inc. Akeso is a Chinese clinical-stage biopharmaceutical company developing novel bispecific antibodies (e.g., ivonescimab, cadonilimab) for oncology; it is a comparable peer as a Chinese-innovator biotech using bispecific/multi-specific antibody technology to address the same solid tumor indications (NSCLC, etc.) SystImmune targets.
• LaNova Medicines: LaNova is a Shanghai-based clinical-stage biopharmaceutical company developing ADC therapies, explicitly referenced as a comparable deal (AstraZeneca partnership at $600M); it is a direct emerging peer in the Chinese ADC innovation landscape pursuing similar solid-tumor targets and platform approaches.

Regional players

• Hansoh Pharmaceutical: Hansoh is a leading Chinese biopharmaceutical company with significant oncology and ADC pipeline activity; it is a regional peer serving similar China and global oncology markets and competes with SystImmune for BD partners, talent, and clinical development capacity in the Chinese biotech ecosystem.
• Innovent Biologics: Innovent is a major Chinese biopharmaceutical company developing innovative oncology biologics including bispecific antibodies (e.g., mazdutide) and ADCs; it is a regional peer comparable to SystImmune in pursuing China-developed oncology biologics for both domestic and global markets through licensing partnerships with multinational pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/2258120

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SystImmune